Inflammation-induced chemokine expression in uveal melanoma cell lines stimulates monocyte chemotaxis

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 8, 2014, Pages 5169-5175

  Jehs, Tina ^a   Faber, Carsten ^a   Juel, Helene B ^a   Bronkhorst, Inge H G ^b   Jager, Martine J ^b   Nissen, Mogens H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemokines; Inflammation; Monocyte migration; Uveal melanoma

Indexed keywords

CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; VASCULOTROPIN;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MONOCYTE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; UVEA MELANOMA;

CHEMOKINES; INFLAMMATION; MONOCYTE MIGRATION; UVEAL MELANOMA;

CELL LINE, TUMOR; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICROARRAY ANALYSIS; MONOCYTES; UVEAL NEOPLASMS;

EID: 84907662150     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14394     Document Type: Article

References (47)

1. Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012; 38: 549-553.
2. Laver NV, McLaughlin ME, Duker JS. Ocular melanoma. Arch Pathol Lab Med. 2010; 134: 1778-1784.
3. Mooy CM, de Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996; 41: 215-228.
4. van den Bosch T, Koopmans AE, Vaarwater J, van den Berg M, de Klein A, Verdijk RM. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance. Invest Ophthalmol Vis Sci. 2013; 54: 7354-7361.
5. De Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996; 234: 34-42.
6. Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012; 53: 5370-5378.
7. Staibano S, Mascolo M, Tranfa F, et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol. 2006; 19: 171-179.
8. Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R, Pulido JS. Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc. 2009; 107: 223-228.
9. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990; 65: 112-115.
10. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006; 86: 231-245.
11. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumorinfiltrating macrophages (CD68({thorn}) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 1414-1421.
12. Jager MJ, Ly LV, El Filali M, Madigan MC. Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes? Prog Retin Eye Res. 2011; 30: 129-146.
13. Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011; 52: 643-650.
14. Herwig MC, Grossniklaus HE. Role of macrophages in uveal melanoma. Expert Rev Ophthalmol. 2011; 6: 405-407.
15. Dunavoelgyi R, Funk M, Sacu S, et al. Intraocular activation of angiogenic and inflammatory pathways in uveal melanoma. Retina. 2012; 32: 1373-1384.
16. Lee CS, Jun IH, Kim TI, Byeon SH, Koh HJ, Lee SC. Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy. Acta Ophthalmol. 2012; 90: e314-e320.
17. Ly LV, Bronkhorst IH, van Beelen E, et al. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci. 2010; 51: 5445-5451.
18. Nagarkatti-Gude N, Bronkhorst IH, van Duinen SG, Luyten GP, Jager MJ. Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Invest Ophthalmol Vis Sci. 2012; 53: 6748-6755.
19. Likhvantseva VG, Slepova OS, Brovkina AF. Interferon status of patients with uveal melanoma [in Russian]. Vestn Oftalmol. 1999; 115: 35-37.
20. Chen PW, Mellon JK, Mayhew E, et al. Uveal melanoma expression of indoleamine 2, 3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res. 2007; 85: 617-625.
21. Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of Tcell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008; 49: 2518-2525.
22. Creyghton WM, De Waard-Siebinga I, Danen EH, Luyten GP, van Muijen GN, Jager MJ. Cytokine-mediated modulation of integrin, ICAM-1 and CD44 expression on human uveal melanoma cells in vitro. Melanoma Res. 1995; 5: 235-242.
23. Hallermalm K, Seki K, De Geer A, et al. Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol. 2008; 180: 3766-3774.
24. MaJ, UsuiY, KezukaT, etal. Costimulatorymolecule expression on human uveal melanoma cells: functional analysis of CD40 and B7-H1. Exp Eye Res. 2012; 96: 98-106.
25. De Waard-Siebinga I, Creyghton WM, Kool J, Jager MJ. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol. 1995; 79: 847-855.
26. Ericsson C, Seregard S, Bartolazzi A, et al. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 2153-2156.
27. Jager MJ, Hurks HM, Levitskaya J, Kiessling R. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol. 2002; 63: 444-451.
28. Bronkhorst IH, Jehs TM, Dijkgraaf EM, et al. Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma. JAMA Ophthalmol. 2014; 132: 614-621.
29. Walker TM, van Ginkel PR, Gee RL, et al. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol. 2002; 120: 1719-1725.
30. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997; 15: 509-518.
31. De Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995; 62: 155-161.
32. Juel HB, Kaestel C, Folkersen L, et al. Retinal pigment epithelial cells upregulate expression of complement factors after co-culture with activated T cells. Exp Eye Res. 2011; 92: 180-188.
33. Juel HB, Faber C, Udsen MS, Folkersen L, Nissen MH. Chemokine expression in retinal pigment epithelial ARPE-19 cells in response to coculture with activated T cells. Invest Ophthalmol Vis Sci. 2012; 53: 8472-8480.
34. Hu Y, Hu X, Boumsell L, Ivashkiv LB. IFN-gamma and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways. J Immunol. 2008; 180: 8057-8065.
35. Khalili JS, Yu X, Wang J, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant. Clin Cancer Res. 2012; 18: 4345-4355.
36. van Dinten LC, Pul N, van Nieuwpoort AF, Out CJ, Jager MJ, van den Elsen PJ. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci. 2005; 46: 24-30.
37. Dennaoui J, Bronkhorst IH, Ly LV, et al. Changes in immunological markers and influx of macrophages following trans-scleral thermotherapy of uveal melanoma. Acta Ophthalmol. 2011; 89: 268-273.
38. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122: 787-795.
39. Shang XZ, Issekutz AC. Enhancement of monocyte transendothelial migration by granulocyte-macrophage colonystimulating factor: requirement for chemoattractant and CD11a/CD18 mechanisms. Eur J Immunol. 1999; 29: 3571-3582.
40. Gomez-Cambronero J, Horn J, Paul CC, Baumann MA. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol. 2003; 171: 6846-6855.
41. Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011; 106: 763-771.
42. Wang T, Ge Y, Xiao M, et al. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature. Pigment Cell Melanoma Res. 2012; 25: 493-505.
43. Varney ML, Olsen KJ, Mosley RL, Singh RK. Paracrine regulation of vascular endothelial growth factor-a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res. 2005; 25: 674-683.
44. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res. 2011; 317: 664-673.
45. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004; 25: 201-209.
46. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol Lett. 2011; 2: 583-589.
47. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, SchalijDelfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008; 49: 505-510.